Copyright © Inderes 2011 - present. All rights reserved.
  • Uusimmat
  • Pörssi
    • Aamukatsaus
    • Osakevertailu
    • Pörssikalenteri
    • Osinkokalenteri
    • Analyysi
    • Artikkelit
    • Sisäpiirin kaupat
  • inderesTV
  • Mallisalkku
  • Foorumi
  • Premium
  • Femme
  • Opi
    • Sijoituskoulu
    • Q&A
    • Analyysikoulu
  • Meistä
    • Seurantayhtiöt
    • Tiimi
Lehdistötiedote

EQL Pharma: Mellozzan® (melatonin) launched in the UK

EQL Pharma

EQL's key product Mellozzan® (tablets) has now been launched in the UK by our partner Medice. Medice specialise in ADHD and have previously launched Mellozzan® successfully in Germany, among other countries. Unlike many other countries in Europe, there is already a growing use of melatonin to treat children with ADHD and sleep problems in the UK. The melatonin tablet market had a turnover of around £10.8 million in 2024, with a volume growth of 32% compared to 2023.

Mellozzan® in the UK is expected to be expanded with the oral solution in 2026. The application is currently under review by the UK Medicines Agency.

About Mellozzan®

Mellozzan® contains the sleep hormone melatonin and is indicated for children with ADHD and sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan® is also indicated for the short-term treatment of jet lag in adults.

About Medice

Medice Arzneimittel Pütter GmbH & Co. KG, founded in 1949 and headquartered in Iserlohn (Germany), is a fully integrated pharmaceutical company with its own GxP capabilities in the development, manufacturing and pan-European and international distribution of pharmaceuticals and medical devices. It is the core of the "Medice - The Health Family" which aims to improve patient care by offering high-quality innovative pharmaceuticals, non-pharmacological interventions and value-added services. For more information, please visit www.medice.com.

Sosiaalinen media
  • Inderes Foorumi
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Yhteystiedot
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Meistä
  • Tiimi
  • Avoimet työpaikat
  • Inderes sijoituskohteena
  • Palvelut pörssiyhtiöille
Sivusto
  • UKK
  • Käyttöehdot
  • Tietosuojaseloste
  • Vastuuvapauslauseke
Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.